FR2906724B1 - Methode d'immunisation contre les 4 serotypes de la dengue. - Google Patents

Methode d'immunisation contre les 4 serotypes de la dengue.

Info

Publication number
FR2906724B1
FR2906724B1 FR0608660A FR0608660A FR2906724B1 FR 2906724 B1 FR2906724 B1 FR 2906724B1 FR 0608660 A FR0608660 A FR 0608660A FR 0608660 A FR0608660 A FR 0608660A FR 2906724 B1 FR2906724 B1 FR 2906724B1
Authority
FR
France
Prior art keywords
serotypes
dengue
immunization against
immunization
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR0608660A
Other languages
English (en)
French (fr)
Other versions
FR2906724A1 (fr
Inventor
Bruno Guy
Remi Forrat
Jean Lang
Veronique Barban
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Pasteur SA
Original Assignee
Sanofi Pasteur SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Pasteur SA filed Critical Sanofi Pasteur SA
Priority to FR0608660A priority Critical patent/FR2906724B1/fr
Priority to TW102119488A priority patent/TW201336508A/zh
Priority to TW096135167A priority patent/TWI406673B/zh
Priority to ARP070104316A priority patent/AR063057A1/es
Priority to CN201310128837XA priority patent/CN103285386A/zh
Priority to CN2007800444299A priority patent/CN101553251B/zh
Priority to EP07858487.7A priority patent/EP2077857B1/fr
Priority to ZA200901816A priority patent/ZA200901816B/xx
Priority to KR1020097008657A priority patent/KR20090064593A/ko
Priority to JP2009530916A priority patent/JP5269796B2/ja
Priority to EP11192672A priority patent/EP2526965A1/fr
Priority to CA002663885A priority patent/CA2663885A1/en
Priority to US11/866,382 priority patent/US7718358B2/en
Priority to MX2009003417A priority patent/MX2009003417A/es
Priority to PCT/FR2007/052054 priority patent/WO2008047023A2/fr
Priority to EP11192665A priority patent/EP2526964A1/fr
Priority to AU2007311792A priority patent/AU2007311792B2/en
Priority to BRPI0719849-3A2A priority patent/BRPI0719849A2/pt
Publication of FR2906724A1 publication Critical patent/FR2906724A1/fr
Application granted granted Critical
Publication of FR2906724B1 publication Critical patent/FR2906724B1/fr
Priority to IL197768A priority patent/IL197768A0/en
Priority to US12/718,308 priority patent/US20100270202A1/en
Priority to IL224572A priority patent/IL224572A/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
FR0608660A 2006-10-04 2006-10-04 Methode d'immunisation contre les 4 serotypes de la dengue. Expired - Fee Related FR2906724B1 (fr)

Priority Applications (21)

Application Number Priority Date Filing Date Title
FR0608660A FR2906724B1 (fr) 2006-10-04 2006-10-04 Methode d'immunisation contre les 4 serotypes de la dengue.
TW102119488A TW201336508A (zh) 2006-10-04 2007-09-20 對抗４種登革熱血清型之免疫方法
TW096135167A TWI406673B (zh) 2006-10-04 2007-09-20 對抗４種登革熱血清型之免疫方法
ARP070104316A AR063057A1 (es) 2006-10-04 2007-09-28 Metodo de inmunizacion contra los 4 serotipos de dengue
EP11192665A EP2526964A1 (fr) 2006-10-04 2007-10-02 Méthode d'immunisation contre les 4 sérotypes de la Dengue
EP07858487.7A EP2077857B1 (fr) 2006-10-04 2007-10-02 Methode d'immunisation contre les 4 serotypes de la dengue
ZA200901816A ZA200901816B (en) 2006-10-04 2007-10-02 Immunisation method against the 4 dengue serotypes
KR1020097008657A KR20090064593A (ko) 2006-10-04 2007-10-02 4 가지 뎅기열 혈청형에 대한 면역화 방법
JP2009530916A JP5269796B2 (ja) 2006-10-04 2007-10-02 ４種のデング血清型に対する免疫付与の方法
EP11192672A EP2526965A1 (fr) 2006-10-04 2007-10-02 Méthode d'immunisation contre les 4 sérotypes de la Dengue
CN201310128837XA CN103285386A (zh) 2006-10-04 2007-10-02 针对4种登革热血清型的免疫方法
US11/866,382 US7718358B2 (en) 2006-10-04 2007-10-02 Method of immunization against the 4 dengue serotypes
MX2009003417A MX2009003417A (es) 2006-10-04 2007-10-02 Metodo de inmunizacion contra los 4 serotipos de dengue.
PCT/FR2007/052054 WO2008047023A2 (fr) 2006-10-04 2007-10-02 Methode d'immunisation contre les 4 serotypes de la dengue
CN2007800444299A CN101553251B (zh) 2006-10-04 2007-10-02 针对4种登革热血清型的免疫方法
AU2007311792A AU2007311792B2 (en) 2006-10-04 2007-10-02 Immunisation method against the 4 dengue serotypes
BRPI0719849-3A2A BRPI0719849A2 (pt) 2006-10-04 2007-10-02 Método de imunização contra os quatro sorotipos da dengue
CA002663885A CA2663885A1 (en) 2006-10-04 2007-10-02 Immunisation method against the 4 dengue serotypes
IL197768A IL197768A0 (en) 2006-10-04 2009-03-23 Immunisation method against the 4 dengue serotypes
US12/718,308 US20100270202A1 (en) 2006-10-04 2010-03-05 Method of Immunization Against the 4 Dengue Serotypes
IL224572A IL224572A (en) 2006-10-04 2013-02-04 A kit for neutralizing antibodies against the four types of dengue virus

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0608660A FR2906724B1 (fr) 2006-10-04 2006-10-04 Methode d'immunisation contre les 4 serotypes de la dengue.

Publications (2)

Publication Number Publication Date
FR2906724A1 FR2906724A1 (fr) 2008-04-11
FR2906724B1 true FR2906724B1 (fr) 2009-03-20

Family

ID=38222583

Family Applications (1)

Application Number Title Priority Date Filing Date
FR0608660A Expired - Fee Related FR2906724B1 (fr) 2006-10-04 2006-10-04 Methode d'immunisation contre les 4 serotypes de la dengue.

Country Status (15)

Country Link
US (2) US7718358B2 (enExample)
EP (3) EP2077857B1 (enExample)
JP (1) JP5269796B2 (enExample)
KR (1) KR20090064593A (enExample)
CN (2) CN103285386A (enExample)
AR (1) AR063057A1 (enExample)
AU (1) AU2007311792B2 (enExample)
BR (1) BRPI0719849A2 (enExample)
CA (1) CA2663885A1 (enExample)
FR (1) FR2906724B1 (enExample)
IL (2) IL197768A0 (enExample)
MX (1) MX2009003417A (enExample)
TW (2) TWI406673B (enExample)
WO (1) WO2008047023A2 (enExample)
ZA (1) ZA200901816B (enExample)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1924280A4 (en) * 2005-08-10 2008-12-10 Acambis Inc VACCINATION AGAINST DENGUE VIRUS INFECTION
FR2903605A1 (fr) * 2006-07-12 2008-01-18 Sanofi Pasteur Sa Methode d'immunisation contre les quatres serotypes de la dengue
FR2909286B1 (fr) * 2006-12-01 2012-06-08 Sanofi Pasteur Methode d'immunisation contre les 4 serotypes de la dengue
MX2010008799A (es) 2008-03-05 2010-09-07 Sanofi Pasteur Proceso para estabilizar una composicion de vacuna que contiene adyuvante.
EP2143440A1 (fr) * 2008-07-09 2010-01-13 Sanofi Pasteur Agent stabilisant et composition vaccinale comprenant un ou plusieurs flavivirus vivants atténués
CN102449172A (zh) * 2009-06-01 2012-05-09 伊维拉根公司 施用针对登革病毒的疫苗的组合物和方法
WO2013188315A1 (en) * 2012-06-10 2013-12-19 Inviragen, Inc. Compositions and methods for administration of vaccines against dengue virus
US8968996B2 (en) 2009-06-01 2015-03-03 Takeda Vaccines, Inc. Compositions and methods for rapid immunization against dengue virus
CA2770888C (en) 2009-08-31 2020-04-14 Gen-Probe Incorporated Dengue virus assay
EP2353609A1 (en) * 2010-02-04 2011-08-10 Sanofi Pasteur Immunization compositions and methods
US10238734B2 (en) * 2010-03-23 2019-03-26 The Regents Of The University Of California Compositions and methods for self-adjuvanting vaccines against microbes and tumors
SG10201704908SA (en) * 2011-06-29 2017-07-28 Emergex Vaccines Holdings Ltd Cytotoxic T-Lymphocyte-Inducing Immunogens For Prevention, Treatment, And Diagnosis Of Dengue Virus Infection
US8895028B2 (en) * 2012-07-20 2014-11-25 Arbovax, Inc. Methods and compositions for dengue virus 3 (DV3) infectious clone
MY168959A (en) * 2012-07-24 2019-01-28 Sanofi Pasteur Vaccine compositions for the prevention of dengue virus infection
WO2014016362A1 (en) 2012-07-24 2014-01-30 Sanofi Pasteur Vaccine compositions for prevention against dengue virus infection
BR112015012515B1 (pt) 2012-11-30 2023-04-11 Sanofi Pasteur Uso de antígenos, construções de ácido nucleico ou vetores virais capazes de expressar uma partícula do tipo vírus (vlp) da dengue e de uma vacina contra sarampo, uma vacina contra caxumba e uma vacina contra rubéola
WO2014093182A1 (en) * 2012-12-14 2014-06-19 Inviragen, Inc. Compositions, methods of administration and uses for trivalent dengue virus formulations
US9861692B2 (en) 2013-06-21 2018-01-09 Merck Sharp & Dohme Corp. Dengue virus vaccine compositions and methods of use thereof
TWI852899B (zh) 2014-09-02 2024-08-21 法商賽諾菲巴斯德公司 疫苗組合物
MX383329B (es) 2014-12-22 2025-03-13 Merck Sharp & Dohme Llc Composiciones de vacuna para el virus del dengue y metodos de uso de las mismas.
EP3316905A1 (en) 2015-07-03 2018-05-09 Sanofi Pasteur Concomitant dengue and yellow fever vaccination
MY194650A (en) * 2015-11-27 2022-12-09 Km Biologics Co Ltd Multivalent dengue vaccine composition comprising a mixture of attenuated dengue viruses from different serotypes
JP7313345B2 (ja) 2017-10-05 2023-07-24 サノフィ・パスツール デング熱に対するブースターワクチン接種のための組成物
ES2908304T3 (es) 2018-09-05 2022-04-28 Takeda Vaccines Inc Dosis unitaria de vacuna contra el dengue y administración de la misma
PH12022550261A1 (en) 2019-08-16 2023-06-26 Takeda Vaccines Inc Methods for preventing dengue and hepatitis a
WO2021174059A1 (en) 2020-02-27 2021-09-02 Takeda Vaccines, Inc. Method for removing host cell dna from virus preparation
WO2023147337A2 (en) 2022-01-25 2023-08-03 Takeda Vaccines, Inc. Large-scale flaviviral vaccine production and manufacture
US20250177511A1 (en) 2022-02-15 2025-06-05 Takeda Vaccines, Inc. Dengue vaccine batch mixing process
WO2023215383A1 (en) 2022-05-04 2023-11-09 Takeda Vaccines, Inc. Computer-based determination of flavivirus infectivity
EP4375381A1 (en) 2022-11-18 2024-05-29 Takeda Vaccines, Inc. A method for determining the proportion of a live, attenuated flavivirus having a nucleotide sequence comprising at least one attenuation locus in a formulation
EP4626574A1 (en) 2022-11-29 2025-10-08 Takeda Vaccines, Inc. Large-scale flaviviral vaccine production and manufacture
WO2025072259A1 (en) 2023-09-25 2025-04-03 Takeda Vaccines, Inc. Coadministration of tetravalent dengue vaccine with hpv vaccine
WO2025122855A1 (en) 2023-12-08 2025-06-12 Takeda Vaccines, Inc. A method for determining the concentration of residual vero cell genomic dna in a sample containing virus obtained from production in vero cells

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996040933A1 (en) 1995-06-07 1996-12-19 The Government Of The United States Of America, Represented By The Secretary Department Of Health And Human Services Infectious dengue 2 virus pdk-53 as quadravalent vaccine
ES2244050T3 (es) 1997-02-28 2005-12-01 Acambis Inc. Vacunas quimericas de flavivirus.
CA2332786A1 (en) 1998-05-29 1999-12-02 Epimmune Inc. Identification of broadly reactive dr restricted epitopes
US6528065B1 (en) 1999-03-26 2003-03-04 The United States Of America As Represented By The Secretary Of The Army Attenuated dengue-3 virus vaccine
JP2002540169A (ja) 1999-03-26 2002-11-26 ウォルター リード アーミー インスティテュート オブ リサーチ 弱毒化デング熱１型ウイルスワクチン
AU4040400A (en) * 1999-03-26 2000-10-16 Walter Reed Army Institute Of Research Attenuated dengue-4 virus vaccine
DE60041250D1 (de) * 1999-03-26 2009-02-12 Us Army Multivalenter dengue-virus impfstoff
US6511667B1 (en) 1999-03-26 2003-01-28 The United States Of America As Represented By The Secretary Of The Army Attenuated dengue-2 virus vaccine
US6632663B1 (en) 1999-09-22 2003-10-14 Aventis Pasteur Limited DNA immunization against chlamydia infection
WO2001060847A2 (en) 2000-02-16 2001-08-23 The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services Avirulent, immunogenic flavivirus chimeras
ATE412738T1 (de) * 2000-05-30 2008-11-15 Univ Mahidol Attenuierte stammen von denguevirus und ihre verwendungen in impfstoffzusammensetzungen
EP1159969A1 (fr) 2000-05-30 2001-12-05 Aventis Pasteur Vaccine composition
AT410634B (de) 2001-02-21 2003-06-25 Franz X Dr Heinz Attenuierte lebendimpfstoffe
CA2966716C (en) 2001-05-22 2019-11-26 The Government Of The United States Of America, As Represented By The Cretary, Department Of Health And Human Services Development of mutations useful for attenuating dengue viruses and chimeric dengue viruses
WO2002095007A2 (en) 2001-05-23 2002-11-28 Dendreon San Diego Llc Conjugates activated by cell surface proteases and therapeutic uses thereof
US7569383B2 (en) 2001-06-01 2009-08-04 Acambis Inc. Chimeric flavivirus vectors
US20040120964A1 (en) * 2001-10-29 2004-06-24 Mikszta John A. Needleless vaccination using chimeric yellow fever vaccine-vectored vaccines against heterologous flaviviruses
EP2295023A1 (en) * 2002-01-15 2011-03-16 Sanofi Pasteur Biologics Co. Flavivirus vaccines
AU2003239932A1 (en) * 2002-05-31 2003-12-19 Acambis, Inc. Tetravalent dengue vaccines
CA2519953C (en) * 2003-03-24 2016-01-05 The Scripps Research Institute Dna vaccine against tumor growth and methods of use thereof
CA2611934C (en) * 2005-06-17 2015-11-03 Sanofi Pasteur Dengue serotype 1 attenuated strain
EP1924280A4 (en) * 2005-08-10 2008-12-10 Acambis Inc VACCINATION AGAINST DENGUE VIRUS INFECTION
FR2903605A1 (fr) * 2006-07-12 2008-01-18 Sanofi Pasteur Sa Methode d'immunisation contre les quatres serotypes de la dengue
FR2909286B1 (fr) * 2006-12-01 2012-06-08 Sanofi Pasteur Methode d'immunisation contre les 4 serotypes de la dengue

Also Published As

Publication number Publication date
FR2906724A1 (fr) 2008-04-11
EP2526965A1 (fr) 2012-11-28
EP2526964A1 (fr) 2012-11-28
US20100270202A1 (en) 2010-10-28
AU2007311792B2 (en) 2013-05-02
CN103285386A (zh) 2013-09-11
TW200826959A (en) 2008-07-01
EP2077857A2 (fr) 2009-07-15
US20080085288A1 (en) 2008-04-10
MX2009003417A (es) 2009-04-09
ZA200901816B (en) 2010-06-30
TW201336508A (zh) 2013-09-16
WO2008047023A2 (fr) 2008-04-24
AR063057A1 (es) 2008-12-23
CN101553251B (zh) 2013-05-22
IL197768A0 (en) 2011-08-01
KR20090064593A (ko) 2009-06-19
JP2010505801A (ja) 2010-02-25
EP2077857B1 (fr) 2013-11-20
BRPI0719849A2 (pt) 2014-04-29
IL224572A (en) 2014-06-30
TWI406673B (zh) 2013-09-01
WO2008047023A3 (fr) 2008-10-23
JP5269796B2 (ja) 2013-08-21
CA2663885A1 (en) 2008-04-24
AU2007311792A1 (en) 2008-04-24
US7718358B2 (en) 2010-05-18
CN101553251A (zh) 2009-10-07

Similar Documents

Publication Publication Date Title
FR2906724B1 (fr) Methode d'immunisation contre les 4 serotypes de la dengue.
FR2909286B1 (fr) Methode d'immunisation contre les 4 serotypes de la dengue
ZA200900155B (en) Method of immunisation against the four serotypes of dengue
EP2318530A4 (en) NEW EPITOP FOR IMMUNIZING AGAINST INFLUENZA VIRUS
PL1896065T3 (pl) Sposób wytwarzania szczepionek
BRPI0814941A2 (pt) Composição de tratamentode semente, e, método de tratamento de semente.
DK2077287T3 (da) Fremgangsmåde til fremstilling af blødt polyurethanskum
PL1993985T3 (pl) Sposób wytwarzania 1,2-propanodiolu
BRPI0810270A2 (pt) "implante de válvula cardíaca e método de implante"
EP1888765A4 (en) METHOD AND COMPOSITIONS FOR DIAGNOSIS OF VENOUS THROMBOEMBOLIC ILLNESSES
PL2035398T3 (pl) Immobilizowany 1,2-benzoizotiazolin-3-on
BRPI0822079A2 (pt) Método, fluido de tratamento ácido, e, composição
CL2007002727A1 (es) Proceso de preparacion de anastrozol; y compuestos intermediarios.
EP2305292A4 (en) TRANSDERMAL IMMUNIZER OF S / O TYPE
FR2909743B1 (fr) Joint d'etancheite.
PL1853220T5 (pl) Sposób wytwarzania pastylek zawierających NLPZ, ich kompozycje, ich zastosowanie medyczne
EP1904097A4 (en) MALARIA MSP-1 C-TERMINAL REINFORCED SUBUNIT VACCINE
ITMO20060388A1 (it) Metodo per la realizzazione di manufatti fotoluminescenti e manufatto fotoluminescente cosi' ottenibile.
ITMI20051910A1 (it) Metodo per la preparazione di colture batteriche probiotiche anallergiche e relativo impiego
ITMI20062515A1 (it) Procedimento per la preparazione di 3,6-di-o-aceti-d-glicali
ITMI20060489A1 (it) Procedimento per la preparazione di 1-beono-3-trifluorometossibenzene
ITMI20061212A1 (it) Metodo per la preparazione di colture batteriche probiotiche anallergiche e relativo impiego
TH0601005638A (th) องค์ประกอบที่ประกอบรวมด้วยริทูซิแมบสำหรับรักษาความเสียหายของข้อ
ITUD20060244A1 (it) Metodo per la realizzazione di una struttura sportiva multifunzionale, e struttura sportiva multifunzionale cosi' realizzata
ITPD20060075A1 (it) Metodo per la preparazione di rivestimenti del tipo mattone-a-vista e rivestimento cosi' ottenuto

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 10

ST Notification of lapse

Effective date: 20170630